Nuvectis Pharma, Inc.

NASDAQ:NVCT

Biotechnology

Healthcare
$20.29 +3.06%

+$0.39 today

Market cap
$697.75M
Beta
-0.07
P/E (TTM)
-11.2
EPS (TTM)
-$1.16
52W Low $5.55High $13.51

Volume 0.19M

Average 0.08M

NVCT Deferred Income Tax

The difference between tax expense recognized and tax actually paid in cash during the period.

Nuvectis Pharma, Inc.NASDAQ: NVCT

Deferred Income Tax · Q1 FY2026 · quarter ended Mar 2026

Deferred income tax outflow grows to $0

Q1 FY2026 deferred income tax was $0, compared with $0 a year earlier. Trailing-twelve-month deferred income tax was $0.

Context

  • Deferred income tax increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly deferred income tax holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$0— YoY
Deferred Income Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Deferred Income Tax history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
—

Deferred Income Tax vs competitors

How NVCT compares with its peers on the latest reported figures

  • NVCT's LTM Mar 2026 deferred income tax of $0 is the largest of the 11 companies compared; the peer median is $0.
NVCT Competitors Peer median
Deferred Income Tax for NVCT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVCTNuvectis Pharma, Inc.LTM Mar 2026$0 ———
NUVBNuvation Bio Inc.LTM Jun 2026$0 ——0.0%
VSTMVerastem, Inc.LTM Mar 2026$0 ——0.0%
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$0 ——0.0%
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$0 ———
JANXJanux Therapeutics, Inc.LTM Mar 2026$0 ——0.0%
IMMXImmix Biopharma, Inc.LTM Mar 2026$0 ———
IMRXImmuneering CorporationLTM Mar 2026$0 ———
MGNXMacroGenics, Inc.LTM Mar 2026$0 ——0.0%
CMPXCompass Therapeutics, Inc.LTM Mar 2026$0 ———
MREOMereo BioPharma Group plcLTM Mar 2026$0 ——0.0%
Peer median (excluding NVCT) $0——0.0%

Competitors are the stored peer set for NVCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(12.89M)(19.09M)(22.26M)(19M)(26.44M)
Depreciation & Amortization00000
Deferred Income Tax00000
Stock-Based Compensation1.89M1.71M4.71M4.86M1.35M
Change in Working Capital1.49M3.82M1.74M1.9M4.4M
Accounts Receivables00000
Inventory00000
Accounts Payables01.85M(139K)(273K)3.78M
Other Working Capital1.49M1.97M1.88M2.17M625K
Other Non-Cash Items00(139K)04.68M
Operating Cash Flow(9.5M)(13.56M)(15.95M)(12.25M)(16.01M)
Capital Expenditures00000
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow00000
Debt Repayment00000
Common Stock Issued15.25M31.88M5.29M12.04M29.11M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities0(4.07M)9.8M(382K)0
Financing Cash Flow15.25M27.81M15.09M11.65M29.11M
Effect of Forex Changes00000
Net Change in Cash5.74M14.25M(867K)(593K)13.1M
Free Cash Flow(9.5M)(13.56M)(15.95M)(12.25M)(16.01M)

Nuvectis Pharma, Inc.

NASDAQ:NVCT

Intrinsic Alpha fair value

Locked

Current Price

$20.29

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.